{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:57:11Z","timestamp":1784289431722,"version":"3.55.0"},"reference-count":32,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We report on 59 Hodgkin lymphoma patients undergoing haploidentical stem cell transplantation (SCT; haplo-SCT) with posttransplant cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis, comparing outcomes based on pretransplant exposure to checkpoint inhibitors (CPIs). Considering pretransplant characteristics, the 2 cohorts (CPI = 29 patients vs no-CPI = 30 patients) were similar, except for the number of prior lines of therapy (6 vs 4; P &amp;lt; .001). With a median follow-up of 26 months (range, 7.5-55 months), by univariate analysis, the 100-day cumulative incidence of grade 2-4 acute GVHD was 41% in the CPI group vs 33% in the no-CPI group (P = .456), whereas the 1-year cumulative incidence of moderate to severe chronic GVHD was 7% vs 8%, respectively (P = .673). In the CPI cohort, the 2-year cumulative incidence of relapse appeared lower compared with the no-CPI cohort (0 vs 20%; P = .054). No differences were observed in terms of overall survival (OS), progression-free survival (PFS), and nonrelapse mortality (NRM) (at 2 years, 77% vs 71% [P = .599], 78% vs 53% [P = .066], and 15% vs 21% [P = .578], respectively). By multivariable analysis, CPI before SCT was an independent protective factor for PFS (hazard ratio [HR], 0.32; P = .037). Stable disease (SD)\/progressive disease (PD) was an independent negative prognostic factor for both OS and PFS (HR, 14.3; P &amp;lt; .001 and HR, 14.1; P &amp;lt; .001, respectively) . In conclusion, CPI as a bridge to haplo-SCT seems to improve PFS, with no impact on toxicity profile.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019001336","type":"journal-article","created":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T15:37:55Z","timestamp":1585582675000},"page":"1242-1249","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7738-997X","authenticated-orcid":false,"given":"Chiara","family":"De Philippis","sequence":"first","affiliation":[{"name":"Department of Hematology, Humanitas Clinical and Research Center\u2013Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faezeh","family":"Legrand-Izadifar","sequence":"first","affiliation":[{"name":"Department of Hematology, Institut Paoli Calmettes, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bramanti","sequence":"first","affiliation":[{"name":"Department of Hematology, Humanitas Clinical and Research Center\u2013Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Giordano","sequence":"first","affiliation":[{"name":"Biostatistic Unit, Humanitas Clinical and Research Center\u2013IRCCS, Rozzano, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Montes de Oca","sequence":"first","affiliation":[{"name":"Department of Hematology, Institut Paoli Calmettes, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9my","family":"Dul\u00e9ry","sequence":"first","affiliation":[{"name":"Department of Hematology, Hospital Saint-Antoine, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda","family":"Bouabdallah","sequence":"first","affiliation":[{"name":"Department of Hematology, Institut Paoli Calmettes, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5511-5276","authenticated-orcid":false,"given":"Angela","family":"Granata","sequence":"first","affiliation":[{"name":"Department of Hematology, Institut Paoli Calmettes, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raynier","family":"Devillier","sequence":"first","affiliation":[{"name":"Department of Hematology, Institut Paoli Calmettes, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Mariotti","sequence":"first","affiliation":[{"name":"Department of Hematology, Humanitas Clinical and Research Center\u2013Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Sarina","sequence":"first","affiliation":[{"name":"Department of Hematology, Humanitas Clinical and Research Center\u2013Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Harbi","sequence":"first","affiliation":[{"name":"Department of Hematology, Institut Paoli Calmettes, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Maisano","sequence":"first","affiliation":[{"name":"Department of Hematology, Institut Paoli Calmettes, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Furst","sequence":"first","affiliation":[{"name":"Department of Hematology, Institut Paoli Calmettes, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pagliardini","sequence":"first","affiliation":[{"name":"Department of Hematology, Institut Paoli Calmettes, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Jean","family":"Weiller","sequence":"first","affiliation":[{"name":"Department of Hematology, Institut Paoli Calmettes, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Lemarie","sequence":"first","affiliation":[{"name":"Department of Hematology, Institut Paoli Calmettes, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Calmels","sequence":"first","affiliation":[{"name":"Department of Hematology, Institut Paoli Calmettes, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3755-4889","authenticated-orcid":false,"given":"Christian","family":"Chabannon","sequence":"first","affiliation":[{"name":"Department of Hematology, Institut Paoli Calmettes, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"first","affiliation":[{"name":"Department of Hematology, Humanitas Clinical and Research Center\u2013Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"first","affiliation":[{"name":"Department of Hematology, Hospital Saint-Antoine, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-9447","authenticated-orcid":false,"given":"Didier","family":"Blaise","sequence":"first","affiliation":[{"name":"Department of Hematology, Institut Paoli Calmettes, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Castagna","sequence":"first","affiliation":[{"name":"Department of Hematology, Humanitas Clinical and Research Center\u2013Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,3,30]]},"reference":[{"issue":"4","key":"2020041411281532400_B1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"2020041411281532400_B2","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"14","key":"2020041411281532400_B3","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"19","key":"2020041411281532400_B4","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"14","key":"2020041411281532400_B5","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2020041411281532400_B6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1200\/JCO.2007.13.2415","article-title":"Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin\u2019s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Sureda","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020041411281532400_B7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3324\/haematol.13441","article-title":"Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin\u2019s lymphoma: identification of prognostic factors predicting outcome","volume":"94","author":"Robinson","year":"2009","journal-title":"Haematologica"},{"issue":"18","key":"2020041411281532400_B8","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood-2009-12-253856","article-title":"Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability","volume":"115","author":"Sarina","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2020041411281532400_B9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3324\/haematol.2011.045757","article-title":"Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin\u2019s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espa\u00f1ol de Linfomas\/Trasplante de M\u00e9dula Osea (GEL\/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"97","author":"Sureda","year":"2012","journal-title":"Haematologica"},{"issue":"5","key":"2020041411281532400_B10","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1634\/theoncologist.2017-0004","article-title":"FDA approval summary: nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma","volume":"22","author":"Kasamon","year":"2017","journal-title":"Oncologist"},{"issue":"10","key":"2020041411281532400_B11","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2020041411281532400_B12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","article-title":"Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation","volume":"25","author":"Ijaz","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2020041411281532400_B13","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.bbmt.2011.06.006","article-title":"The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade","volume":"17","author":"Carreras","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"2020041411281532400_B14","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020041411281532400_B15","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"issue":"17","key":"2020041411281532400_B16","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/bloodadvances.2018019208","article-title":"Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide","volume":"2","author":"Schoch","year":"2018","journal-title":"Blood Adv"},{"issue":"23","key":"2020041411281532400_B17","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1182\/bloodadvances.2019000134","article-title":"PTCy ameliorates GVHD by restoring regulatory and effector T-cell homeostasis in recipients with PD-1 blockade","volume":"3","author":"Ikegawa","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"2020041411281532400_B18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020041411281532400_B19","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2020041411281532400_B20","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2020041411281532400_B21","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1182\/blood-2006-07-034348","article-title":"Hyperacute GVHD: risk factors, outcomes, and clinical implications","volume":"109","author":"Saliba","year":"2007","journal-title":"Blood"},{"issue":"8","key":"2020041411281532400_B22","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"27","key":"2020041411281532400_B23","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"21","key":"2020041411281532400_B24","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"2020041411281532400_B25","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/bmt.2012.282","article-title":"Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation","volume":"48","author":"Iacobelli","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2020041411281532400_B26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2019.04.006","article-title":"Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation","volume":"115","author":"Manson","year":"2019","journal-title":"Eur J Cancer"},{"issue":"18","key":"2020041411281532400_B27","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"2020041411281532400_B28","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/s41409-019-0500-x","article-title":"Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients","volume":"54","author":"Granata","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2020041411281532400_B29","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.bbmt.2019.05.017","article-title":"Peripheral blood stem cells versus bone marrow for T cell-replete haploidentical transplantation with post-transplant cyclophosphamide in Hodgkin lymphoma","volume":"25","author":"Mariotti","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020041411281532400_B30","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.bbmt.2018.12.767","article-title":"Development of grade II acute graft-versus-host disease is associated with improved survival after myeloablative HLA-matched bone marrow transplantation using single-agent post-transplant cyclophosphamide","volume":"25","author":"McCurdy","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2020041411281532400_B31","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1182\/blood-2017-05-780668","article-title":"NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications","volume":"131","author":"Russo","year":"2018","journal-title":"Blood"},{"issue":"18","key":"2020041411281532400_B32","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1182\/blood-2014-11-608406","article-title":"Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation","volume":"125","author":"Roberto","year":"2015","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/7\/1242\/1724260\/advancesadv2019001336.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/7\/1242\/1724260\/advancesadv2019001336.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T15:29:32Z","timestamp":1586878172000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/7\/1242\/454149\/Checkpoint-inhibition-before-haploidentical"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,30]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,4,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019001336","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,30]]}}}